Daniel Judge to Aged
This is a "connection" page, showing publications Daniel Judge has written about Aged.
Connection Strength
0.546
-
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
Score: 0.058
-
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid?Cardiomyopathy. J Am Coll Cardiol. 2019 07 23; 74(3):285-295.
Score: 0.054
-
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
Score: 0.047
-
Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. J Card Fail. 2017 Apr; 23(4):340-344.
Score: 0.046
-
Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
Score: 0.030
-
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct; 2(5):428-35.
Score: 0.027
-
Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
Score: 0.023
-
Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J. 2021 03; 233:122-131.
Score: 0.015
-
Endomyocardial Biopsy Characterization of Heart?Failure With Preserved Ejection?Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020 09; 8(9):712-724.
Score: 0.015
-
FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2020 04; 57(4):254-257.
Score: 0.014
-
Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018 Sep; 25(3):174-179.
Score: 0.013
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
Score: 0.013
-
Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. Circ Genom Precis Med. 2018 07; 11(7):e002237.
Score: 0.013
-
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep; 24(3):194-204.
Score: 0.012
-
Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
Score: 0.012
-
Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017 Apr; 36(4):380-385.
Score: 0.012
-
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
Score: 0.011
-
Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
Score: 0.011
-
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
Score: 0.010
-
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
Score: 0.010
-
Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
Score: 0.010
-
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015 Apr 07; 36(14):847-55.
Score: 0.010
-
Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015 Apr; 12(4):716-25.
Score: 0.010
-
Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014 Dec; 3(6):e001471.
Score: 0.010
-
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
Score: 0.009
-
Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013 Nov 05; 62(19):1772-9.
Score: 0.009
-
Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
Score: 0.009
-
Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013 May-Jun; 22(3):189-94.
Score: 0.009
-
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
Score: 0.008
-
The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm. 2006 Apr; 3(4):435-42.
Score: 0.005
-
Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec 20; 112(25):3823-32.
Score: 0.005
-
Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block. Circulation. 2004 Nov 30; 110(22):3404-10.
Score: 0.005